Wanbury Limited, a leading player in Active Pharmaceutical Ingredients (APIs) and branded formulations celebrated a game-changing milestone: official confirmation of first sales, customer invoicing and commercial shipment to European customer for its newly commercialized anaesthetic API from the cutting-edge Tanuku facility.

This achievement validates global demand and catapults Wanbury into high-growth acceleration. Just months after launching commercial production, Wanbury has secured orders and completed invoicing and product shipment, a clear testament to our operational excellence and market- leading product quality. This success story is set to multiply as we ramp up production capacity at Tanuku.

“First sales confirmed, invoicing and product shipment completed, production scaling fast. Our expansion momentum positions us for exponential growth and market leadership,” declared Mohan Rayana, Whole-time Director of Wanbury Limited.